Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 92

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 92
---
 as (i) interim Chairman and Chief Executive Officer from October 2024 to November 2024, (ii) Vice Chairman of the board of directors from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024. (5)Phoenix Biotech Sponsor, LLC beneficially owned more than 5% of our outstanding capital stock at the time of the transaction.

50 Registered Direct Offering in February 2025 On February 7, 2025, we issued and sold 15,000shares of our Common Stock and 112,551 Pre -FundedWarrants to purchase 112,551shares of our Common Stock together with 127,551 February 2025 Common Warrants to purchase 127,551shares of Common Stock. Each share of Common Stock or Pre -FundedWarrant is being sold together with a February 2025 Common Warrant to purchase one share of Common Stock. The shares of Common Stock or Pre -FundedWarrants and accompanying February 2025 Common Warrants were issued separately and were immediately separable upon issuance. Brian Atwood, one of our directors, purchased an aggregate of 25,510 Pre -FundedWarrants and accompanying February 2025 Common Warrants to purchase 25,510shares of Common Stock for a total purchase price of approximately $1 million at this offering. Other On April 22, 2025, pursuant to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth PIPE Financing”), 6,250shares of the Series D Preferred Stock to investors in exchange for the receipt of 1,000,279shares of the Stella Series D Preferred Stock in lieu of cash, in which a portion of the Stella Series D Preferred Stock was owned by a related party investor. The investor is a majority shareholder of Stella Diagnostics, Inc. and has representation on the board of directors thereof. During the nine months ended September 30, 2025 and for the period from February 14, 2024 to September 30, 2024, the Company incurred a consulting fee of $190,000 and $75,000 to members of the Company’s board of directors, respectively. Policies and Procedures for Related Party Transactions We have adopted a code of conduct and ethics requiring us to avoid, wherever possible, all conflicts of interests, except under guidelines or resolutions approved by the board